Related Experiment Video
Updated: Jul 7, 2025
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.0K
Targeting factor XI and factor XIa to prevent thrombosis.
David Gailani1, Andras Gruber2
1The Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
Blood
|December 24, 2023
Summary
New anticoagulants targeting factor XI (FXI) and factor XIa (FXIa) show promise for preventing thrombosis with potentially less bleeding risk than current therapies.
Area of Science:
- Hematology
- Pharmacology
- Cardiovascular Medicine
Background:
- Direct oral anticoagulants (DOACs) are widely used for anticoagulation but carry a risk of serious bleeding.
- Factor XI (FXI) and its activated form, factor XIa (FXIa), are implicated in thrombosis.
- Targeting FXI/FXIa may offer a safer alternative for anticoagulation.
Approach:
- Review of preclinical, nonclinical, and clinical studies on FXI/FXIa inhibitors.
- Evaluation of FXI's role in normal and abnormal coagulation.
- Analysis of early clinical trial data (Phase 2) for FXI/FXIa inhibitors.
Key Points:
- FXI/FXIa inhibitors demonstrate efficacy in preventing venous thromboembolism post-orthopedic surgery.
- Inhibitors of FXI/FXIa show reduced bleeding compared to DOACs in patients with heart disease.
- Phase 3 trials are underway to compare FXI/FXIa inhibitors against standard treatments.
Conclusions:
- FXI/FXIa inhibitors represent a promising new class of anticoagulants.
- These agents may provide effective thrombosis prevention with an improved bleeding profile.
- Further clinical trials are essential to confirm the safety and efficacy of FXI/FXIa inhibition.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
706
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
706
01:16Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K
01:09Coagulation
6.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.8K
01:24Disorders of Hemostasis
922
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
922